Patient Global Impression of Change much or very much improved · adults with moderate or severe pain associated with painful diabetic neuropathy
1 finding from 1 review
Lack of efficacy withdrawal · adults with moderate or severe pain associated with painful diabetic neuropathy
1 finding from 1 review
Somnolence · adults with moderate or severe pain associated with painful diabetic neuropathy
1 finding from 1 review
Dizziness · adults with moderate or severe pain associated with painful diabetic neuropathy
1 finding from 1 review
Withdrawals due to adverse events · adults with moderate or severe pain associated with painful diabetic neuropathy
1 finding from 1 review
Patient Global Impression of Change much or very much improved · adults with moderate or severe pain associated with postherpetic neuralgia
1 finding from 1 review
mg pregabalin · adults with moderate or severe neuropathic pain
2 findings from 1 review
no estimate extracted
300 participants
GRADE not reported
no estimate extracted
600 participants
GRADE not reported
Risk for at least one adverse event per patient · adults with moderate or severe neuropathic pain
1 finding from 1 review
Serious AE · adults with moderate or severe neuropathic pain
1 finding from 1 review
Lack of efficacy withdrawal · adults with moderate or severe pain associated with postherpetic neuralgia
1 finding from 1 review
Somnolence · adults with moderate or severe pain associated with postherpetic neuralgia
1 finding from 1 review
Dizziness · adults with moderate or severe pain associated with postherpetic neuralgia
1 finding from 1 review
Withdrawals due to adverse events · adults with moderate or severe pain associated with postherpetic neuralgia
1 finding from 1 review
Participant‐reported pain relief of 30% or greater · adults with moderate or severe pain associated with postherpetic neuralgia
1 finding from 1 review
Participant‐reported pain relief of 50% or greater · adults with moderate or severe pain associated with postherpetic neuralgia
1 finding from 1 review
Failure to maintain remission · people with moderate to severe Crohn's disease in remission
Ustekinumab showed no clear difference in failure to maintain clinical remission compared with placebo (moderate certainty).
2 findings from 1 review
Adverse events · people with moderate to severe Crohn's disease in remission
Briakinumab showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people with moderate to severe Crohn's disease in remission
Briakinumab showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with moderate to severe Crohn's disease in remission
Briakinumab showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Failure to maintain clinical response · people with moderate to severe Crohn's disease in remission
Ustekinumab probably leads to lower failure to maintain clinical response compared with placebo (moderate certainty).
2 findings from 1 review